Solid Tumor Treatment via Augmentation of Bioactive C6 Ceramide Levels with Thermally Ablative Focused Ultrasound.

Solid Tumor Treatment via Augmentation of Bioactive C6 Ceramide Levels with Thermally Ablative Focused Ultrasound.
复制标题

通过热消融聚焦超声提高生物活性 C6 神经酰胺水平来治疗实体瘤。

DOI:
10.1101/2023.03.23.532394
复制
发表时间:
2023
期刊:
bioRxiv : the preprint server for biology
影响因子:
--
通讯作者:
Price,RichardJ
Price,RichardJ
中科院分区:
--
文献类型:
--
作者:
Thim,EAndrew;Fox,Todd;Deering,Tye;Vass,LukeR;Sheybani,NatashaD;Kester,Mark;Price,RichardJ

文献摘要

参考文献

相似文献

利用聚焦超声(FUS)的稀疏扫描部分热消融(TA)可以用于治疗实体瘤并增加全身施用的治疗剂的递送。此外,C6-神经酰胺负载的纳米脂质体(CNL),其依赖于增强的渗透和保留(EPR)作用来递送,已经显示出治疗实体瘤的前景,并且正在临床试验中进行测试。在这里,我们的目的是确定CNLs是否与TA协同控制4 T1乳腺肿瘤。CNL单药治疗4 T1肿瘤通过EPR效应产生显著的肿瘤内生物活性C6积累,但肿瘤生长不受控制。TA使生物活性C6积累比EPR效应增加约12.5倍。此外,TA + CNL引起长链与极长链神经酰胺比率的变化(即,C16/24和C18/C24),可能有助于肿瘤控制。尽管如此,肿瘤内神经酰胺水平的这些变化仍然不足以赋予肿瘤生长控制超过当与TA与对照“幽灵”纳米脂质体(GNL)组合时所实现的控制。虽然这种协同作用的缺乏可能是由于增加的“促肿瘤”鞘氨醇-1-磷酸(S1 P)水平,但这是不可能的,因为TA + CNL的S1 P水平仅表现出中度和统计学上不显著的增加。体外研究表明,4 T1细胞对C6具有高度抗性,这为TA不能与CNL协同作用提供了最可能的解释。因此,虽然我们的研究结果表明稀疏扫描TA是一种有效的方法,可以显著增强CNL的递送,并在长链与超长链神经酰胺的比例中产生“抗肿瘤”变化,但肿瘤对C6的耐药性仍然是某些实体瘤类型的限速因素。
Sparse scan partial thermal ablation (TA) with focused ultrasound (FUS) may be deployed to treat solid tumors and increase delivery of systemically administered therapeutics. Furthermore, C6-ceramide-loaded nanoliposomes (CNLs), which rely upon the enhanced-permeation and retention (EPR) effect for delivery, have shown promise for treating solid tumors and are being tested in clinical trials. Here, our objective was to determine whether CNLs synergize with TA in the control of 4T1 breast tumors. CNL monotherapy of 4T1 tumors yielded significant intratumoral bioactive C6 accumulation by the EPR effect, but tumor growth was not controlled. TA increased bioactive C6 accumulation by ~ 12.5-fold over the EPR effect. In addition, TA + CNL caused shifts in long-chain to very-long-chain ceramide ratios (i.e., C16/24 and C18/C24) that could potentially contribute to tumor control. Nonetheless, these changes in intratumoral ceramide levels were still insufficient to confer tumor growth control beyond that achieved when combining with TA with control “ghost” nanoliposomes (GNL). While this lack of synergy could be due to increased “pro-tumor” sphingosine-1-phosphate (S1P) levels, this is unlikely because S1P levels exhibited only a moderate and statistically insignificant increase with TA + CNL. In vitro studies showed that 4T1 cells are highly resistant to C6, offering the most likely explanation for the inability of TA to synergize with CNL. Thus, while our results show that sparse scan TA is a powerful approach for markedly enhancing CNL delivery and generating “anti-tumor” shifts in long-chain to very-long-chain ceramide ratios, resistance of the tumor to C6 can still be a rate-limiting factor for some solid tumor types.Graphical Abstract
DOI: 10.1093/nar/11.10.3123
发表时间: 1983-05
影响因子: 14.9
作者:
N. F. Kaufer;H. M. Fried;W. F. Schwindinger;M. Jasin;Jonathan;R. Warner
通讯作者: N. F. Kaufer;H. M. Fried;W. F. Schwindinger;M. Jasin;Jonathan;R. Warner
影响酿酒酵母 tRNA 剪接核酸内切酶活性的突变。
DOI: --
发表时间: 1988
期刊: Genetics
影响因子: 3.3
作者:
Mark Winey;M. Culbertson
通讯作者: M. Culbertson
酵母 SRM1 蛋白和人类 RCC1 蛋白具有相似的功能。
DOI: 10.1091/mbc.2.10.781
发表时间: 1991
期刊: Cell regulation
影响因子: --
作者:
Clark,KL;Ohtsubo,M;Nishimoto,T;Goebl,M;SpragueJr,GF
通讯作者: SpragueJr,GF
DOI: 10.1002/j.1460-2075.1991.tb08068.x
发表时间: 1991-05-01
期刊: EMBO JOURNAL
影响因子: 11.4
作者:
OHTSUBO, M;YOSHIDA, T;NISHIMOTO, T
通讯作者: NISHIMOTO, T
RCC1蛋白是染色体凝结发作的调节剂,位于细胞核中并与DNA结合。
DOI: 10.1083/jcb.109.4.1389
发表时间: 1989-10
影响因子: 7.8
作者:
Ohtsubo, M;Okazaki, H;Nishimoto, T
通讯作者: Nishimoto, T